Medical Marijuana To Be Reclassified To Schedule III Substance

[ad_1] by Nahlah Abdur-Rahman April 23, 2026

The drug could be formally reclassified as a Schedule III substance, itemizing its standing amongst painkillers.

The U.S. Justice Division has moved ahead with reclassifying marijuana as a much less harmful substance.

NBC Information reviews that the Justice Division will reclassify state-licensed medical marijuana. The substance is presently listed as a Schedule I drug on the Drug Enforcement Administration’s web site.

Appearing Legal professional Normal Todd Blanche shared on X in regards to the Trump administration’s push to instantly reschedule the drug. The consequence would develop alternatives within the rising hashish trade and its medical utilization.

Below the decisive management of @POTUS, this Division of Justice is delivering on his promise to enhance American healthcare. This consists of:

• Instantly rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule IIl

• Ordering a brand new,… pic.twitter.com/DUtqKQgavl

— Appearing AG Todd Blanche (@DAGToddBlanche) April 23, 2026

“These actions will allow extra focused, rigorous analysis into marijuana’s security and efficacy, increasing sufferers’ entry to remedies and empowering medical doctors to make better-informed healthcare choices,” wrote Blanche.

At the moment, marijuana is deemed a Schedule I drug, detailed as “no presently accepted medical use and a excessive potential for abuse,” in accordance with the DEA. Now, the Marijuana Coverage Challenge confirmed that the substance’s official swap to a Schedule III classification would checklist it among the many likes of painkillers and testosterone.

In response to Yahoo Finance, this reclassification would have a number of impacts on medical marijuana utilization. This issuance would pave the best way for additional analysis into its medicinal potential, enabling extra healthcare professionals to advocate the drug to eligible sufferers, as emphasised by Blanche in a press release.

“The Division of Justice is delivering on President Trump’s promise to develop Individuals’ entry to medical remedy choices,” said the lawyer basic in a press launch. “This rescheduling motion permits for analysis on the protection and efficacy of this substance, in the end offering sufferers with higher care and medical doctors with extra dependable data.”

Final December, President Donald Trump signed an govt order that cleared the best way for the DEA to approve a reclassification. The order urged for extra medical analysis on the drug as federal regulation of marijuana shifts.

This information has already impacted the inventory market, boosting the inventory costs of cannabis-affiliated firms akin to Cover Progress and Tilray Manufacturers. One other optimistic impact for such corporations is that looser restrictions may result in decrease tax burdens and wider funding alternatives for newer firms.

With the newest order to reclassify medical marijuana issued, the federal authorities additionally scheduled a brand new listening to, set for June 29, to vary marijuana’s authorized standing at massive.